Antihypertensives App Store rankings

Track Antihypertensives App Store rankings across 40+ countries. by ATIF ELNIL • 0.0★ (0 ratings) • Medical

Description

A comprehensive, evidence-based antihypertensive prescribing reference for qualified healthcare professionals. Built on NICE NG136 (2023), ESC/ESH 2023, and BHS guidelines — covering over 30 drugs across 7 drug classes, with dosing, indications, contraindications, monitoring, and landmark trial evidence. WHAT'S INSIDE • NICE NG136 Step Therapy — step-by-step treatment pathway with BP targets for all age groups and high-risk populations • ACE Inhibitors — ramipril, lisinopril, perindopril, enalapril with doses, monitoring protocol, and contraindications • Angiotensin Receptor Blockers — losartan, candesartan, valsartan, irbesartan, olmesartan with trial evidence • Calcium Channel Blockers — dihydropyridines (amlodipine, felodipine, nifedipine, lercanidipine) and non-dihydropyridines (verapamil, diltiazem) • Beta-Blockers — bisoprolol, carvedilol, metoprolol succinate, labetalol, atenolol with role in HTN and full contraindication table • Diuretics — thiazide-like (indapamide, chlortalidone, bendroflumethiazide), aldosterone antagonists (spironolactone, eplerenone), loop diuretics • Other Agents — alpha-blockers, vasodilators, centrally acting agents, SGLT2 inhibitors in cardiorenal hypertension • Compelling Indications — drug choice by comorbidity: heart failure, diabetes, CKD, post-MI, AF, stroke, pregnancy, gout, phaeochromocytoma, aortic dissection • Resistant Hypertension — definition, secondary causes investigation table, Step 4 treatment algorithm (PATHWAY-2), renal denervation • 18 tappable landmark trial references — HOPE, ASCOT, RALES, ALLHAT, ADVANCE, LIFE, PATHWAY-2, PROGRESS, ONTARGET and more KEY FEATURES • Font size controller (A− / A+) for accessibility • Fast tab-based navigation within each drug class • Offline — no internet connection required • No ads, no subscriptions, no sign-in required • Designed for rapid bedside and clinical use • Based on current UK and European guidelines (2023) DISCLAIMER For use by qualified healthcare professionals only. This app is not a regulated medical device and does not replace clinical judgement. Always verify doses against the current BNF before prescribing. Developed by Dr Atif Elnil MBBS MRCP, St George's University Hospital, London, UK.